April 2020 HSC Section 4 - Plastic and Reconstructive Problems

J A M A CAD D ERMATOL V OLUME 77, N UMBER 1

Adil and Godwin

Results, mean difference hair density/cm 2 (SD) * between baseline and follow-up

(SD not provided) Placebo: 32.3 ( 6 59.2)

Continued

48 Finasteride: 16 (4) Placebo: 4 (5)

48 Finasteride: 7.2 (17.22) Placebo: 10.1 (16.79)

48 Finasteride: 9.6 (19.3) Placebo: 20.6 (18.97)

48 Finasteride: 2.3 (13.09) Placebo: 0.1 (12.8)

24 Dutasteride: 12.2 (23.6) Placebo: 4.7 (16.8)

24 Dutasteride: 94.6

Follow-up, weeks

Article Sex Study population details Intervention group Control Placebo N = 9

Placebo

N = 91

Placebo

N = 160

Placebo

N = 12

Placebo

N = 75

Placebo

N = 50

Finasteride 1 mg/day N = 93

Finasteride 1 mg/day N = 9

Finasteride 1 mg/day N = 166

Finasteride 1 mg/day N = 14 Dutasteride

0.5 mg/day N = 73

Dutasteride 0.5 mg/day N = 61

results, surgical therapy for scalp hair loss, therapy of scalp hair loss, nonidentical twin pairs Race: 100% white AGA type: NH type II-V

Neste et al 2000 25 Men Mean age: 29.8 years Exclusion: surgical correction of hair loss, use of minoxidil within past year, (anti) androgenic drugs use of systemic drugs Race: N/S AGA type: NH IIv-V Leyden et al 1999 26 Men Mean age: 32.5 years Exclusion: N/S Race: N/S AGA type: NH II-III Whiting et al 1999 27 Men Mean age: N/S Exclusion: N/S Race: N/S

Eun et al 2010 28 Men Mean age: 37.8 years Exclusion: significant lab value abnormality, (anti)androgenic use within 6 months, finasteride use within past 12 months, use of dutasteride. AGA type: NH type IIIv-V

Olsen et al 2006 29 Men Mean age: 36.4 years Exclusion: use of 5a-reductase inhibitor or any medication for alopecia in past 6 months, clinically significant health problems, use of any androgenic or antiandrogenics in past 6 months Country: US AGA type: NH IIIv-V

Stough et al 2002 24 Men Mean age: 38.6 years Exclusion: illness that might confound

AGA type: N/S

Supplementary Table I. Cont’d

97